Unverified50% confidenceFactExact time
Large clinical trials such as LEADER and SUSTAIN-6 have confirmed that semaglutide can significantly reduce the risk of major adverse cardiovascular events.
1
Sources
50%
Confidence
Long-term
Relevance
10/11/2026
First Seen
Sources
Related Entities
Related Claims
Cite This Claim
Stable URI
https://kongchang.com/claim/998664API
curl https://kongchang.com/api/v1/knowledge/claims/998664MCP
get_claim(id=998664)